Freitag, 29. März 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms

Rekrutierend

NCT-Nummer:
NCT03624712

Studienbeginn:
Januar 2012

Letztes Update:
14.02.2024

Wirkstoff:
-

Indikation (Clinical Trials):
Neoplasms, Uterine Neoplasms

Geschlecht:
Frauen

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
University Hospital Tuebingen

Collaborator:
University Hospital Heidelberg, University of Homburg, University Hospital Freiburg,

Studienlocations
(1 von 1)

University Hospital Tuebingen, Department of Women's Health
72076 Tuebingen
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Miriam Linneweh, Dr
Phone: +4970712982211
E-Mail: miriam.linneweh@med.uni-tuebingen.de
» Ansprechpartner anzeigen

Studien-Informationen

Brief Summary:

Evaluation of clinical, therapeutic and prognostic relevance of new experimental results as

well as optimization of therapeutic models and development of a new algorithm for therapeutic

plan and therapy in patients with uterine neoplasm

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Confirmed uterine malignancy ( cervical cancer, endometrial cancer, sarcoma)

- If operable: surgical primary therapy: laparoscopic/robot-assisted or open radical

gyneco-oncological surgery

- Written consent

- Willingness and ability to participate in all study-specific procedures

- Age ≥ 18 years

Exclusion Criteria:

- Severe and acute general disease in the last 4 weeks

- Acute or chronic psychiatric disorders

- Other factors questioning study participation (e.g. acute psychosocial stress,

insufficient understanding of nature and consequences of the study, inadequate skills

of the German language)

Studien-Rationale

Primary outcome:

1. CTC and DTC analysis (Time Frame - 12 months):
Counting the number of tumor cells in blood and bone marrow

2. HPV (Time Frame - 12 months):
Analysis of HPV types by DNA tests in peripheral blood, bone marrow, sentinel-lymph node, cervical-, endometrial- and myometrial-tissue, intraperitoneal wash fluid

3. DNA (Time Frame - 12 months):
Determination of DNA in peripheral blood

4. Douglas cytology (Time Frame - 12 months):
Intraperitoneal wash fluid

5. Proteomic analysis (Time Frame - 12 months):
Analysis of proteins by mass spectrometry in removed uterine and sentinel lymph node tissue

6. Sentinel lymph nodes (Time Frame - 12 months):
Number of detectable lymph nodes by Tc99m- and indocyanine green-labeling

7. Peripheral nerve conduction velocity (Time Frame - 12 months):
Intra- and interindividual comparison of N. obturatorius, N. pudendus between pre an post radical gynecological surgery

8. Urodynamic- cystomanometry between pre an post radical gynecological surgeryuroflowmetry (Time Frame - 12 months):
pressur/volume relationship

9. CTC and DTC analysis (Time Frame - 12 months):
Identification and quantification of genetic variants and mutations

10. Urodynamic- urethral pressure profile between pre an post radical gynecological surgeryuroflowmetry (Time Frame - 12 months):
cm H20

11. Urodynamic- uroflowmetry between pre an post radical gynecological surgeryuroflowmetry (Time Frame - 12 months):
rate of flow of urine

Geprüfte Regime

  • uterine neoplasms:
    Analysis of circulating (CTC) and disseminating tumor cells (DTC), determination of Human Papilloma Virus (HPV), Douglas cytology, DNA analysis in blood, proteome analysis, sentinel lymph node detection

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.